fbpx

Proteomics - Article & Videos

Quanterix Nearly Completes Strategic Revamp
November 30. 2023. 4 mins read

When a company runs into systemic problems with their product or service, transparency is a...

Olink Stock: An Emerging Leader in Proteomics?
July 21. 2023. 5 mins read

Of all the technologies we cover, those that fall under “life sciences” are least likely...

Proteomics Stocks | The Latest News & Updates
June 27. 2023. 1 min read

Proteomics stocks like Codexis CDXS, Seer SEER, Somalogic SLGC, Olink OLK, Quanterix QTRX, Nautilus Biotechnology...

Checking in With Seven Proteomics Stocks
June 26. 2023. 6 mins read

ChatGPT writes a few canned emails and the market goes mental because generative AI is...

Seven Proteomics Stocks: Finding the Best One
August 28. 2022. 8 mins read

If you’ve been on this planet for 70 years, you would have been present for...

Why Quanterix Stock is Dropping Like a Rock
August 9. 2022. 6 mins read

Last week’s news cycle was dominated by a headline that almost makes you shed a...

Codexis Stock: A Risky Play on Enzymes
March 6. 2022. 5 mins read

A great interview question to ask a fresh-faced MBA goes something like this. “Take the...

Gandeeva Therapeutics and Cryogenic Electron Microscopy
February 3. 2022. 6 mins read

Nanotechnology was supposed to change the world until it didn’t. Carbon nanotubes and graphene resulted...

SomaLogic Stock: A Significant First-Mover Advantage?
January 11. 2022. 5 mins read

Proteomics – the study of proteins – is incredibly complex stuff. That’s why fund managers...

Olink Stock (OLK) – A Lesser Known Play on Proteomics
August 1. 2021. 4 mins read

Figuring out how much to tax the commoners is a tricky problem to solve. Tax...

Quanterix Stock: A Way to Play the Proteomics Boom
July 23. 2021. 6 mins read

Yesterday’s news cycle was dominated by a headline that makes you almost shed a tear....

Asimov – Building Tools to Program Living Cells
May 2. 2021. 7 mins read

Blockbusters – drugs with annual sales of at least $1 billion – are to pharma...